Loading patent…
AssigneeEisai Co., Ltd.
InventorsJames Martin Staddon, Lee Laurence Rubin, Kurt Herrenknecht, Mary Louise Morgan
Estimating the term…
Permeability of the blood-brain barrier and other physiological barriers can be modulated by the degree of tyrosine phosphorylation of proteins. Agents which promote tyrosine protein dephosphorylation reduce the permeability of the blood-brain barrier and those which promote phosphorylation increase permeability. Increasing blood-brain barrier permeability is useful in delivering drugs having a desired effect upon the central nervous system; decreasing blood-brain barrier permeability and other physiological barrier permeability is useful in preventing undesired compounds reaching the CNS and in certain clinical conditions.
A method for reducing permeability of a physiological barrier comprising adherens junctions and/or tight junctions in a first subject suffering from a central nervous system (CNS) disorder or other disorder, wherein said CNS or other disorder is characterized by increased permeability of a physiological barrier relative to the permeability of said barrier in a second subject not suffering from said CNS or other disorder, wherein said CNS or other disorder is characterized by increased permeability of said physiological barrier due to enhanced tyrosine phosphorylation, said method comprising administering to said first subject an effective amount of an agent which promotes tyrosine protein dephosphorylation of at least one component of a cadherin/catenin complex in said adherens junctions and/or tight junctions.
A method for reducing permeability of adherens junctions and/or tight junctions in a first subject suffering from a central nervous system (CNS) disorder or other disorder, wherein said CNS or other disorder is characterized by increased permeability of adherens junctions and/or tight junctions due to enhanced tyrosine phosphorylation, relative to the permeability of said junctions in a second subject not suffering from CNS or other disorder, said method comprising administering to said first subject an effective amount of an agent which promotes tyrosine protein dephosphorylation of at least one component of a cadherin/catenin complex in said adherens junctions and/or tight junctions.
Dependencies are inferred from the claim text.